Radiopharm Theranostics Ltd has released a press release.
Completion of preclinical data package for RAD 402
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Approval received to expand RAD204 Phase 1 trial
- RAD 301 shows strong imaging potential in pancreatic cancer
- RAD increases ownership in Radiopharm Ventures to 75%
- FDA IND approval for Phase 2b trial in brain metastases
- First patient dosed in Phase 1 therapeutic lung cancer trial
Later from Radiopharm Theranostics
- Response to ASX Aware Letter
- RAD 202 receives approval to start Phase 1 therapeutic trial
- Strategic Co-Development Partnership with Lantheus for Aus
- Lantheus increases shareholding in RAD with A$8m placement
- Clinical trial data shows RAD 101 detects Brain Metastases
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics